Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Pertuzumab Plus High-Dose Trastuzumab Induces Clinical Benefit in HER2+ Metastatic Breast Cancer With CNS Metastases

May 17th 2021

Despite a modest central nervous system overall response rate, the combination of pertuzumab and high-dose trastuzumab was found to induce clinical benefit in 68% of patients with HER2-positive metastatic breast cancer enrolled to the phase 2 PATRICIA trial.

Selective Kinase Inhibitors Push the Envelope in RET or NTRK Fusion–Positive NSCLC

May 17th 2021

Jose Pacheco, MD, discusses key agents that have significantly improved the care of patients with NSCLC harboring RET or NTRK fusions and efforts being made to address resistance challenges.

NKT Cells Co-Expressing GD2-CAR, IL-15 Can Induce Complete Remissions in Pediatric Neuroblastoma

May 15th 2021

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

Isatuximab, Melflufen Combos Seek to Move the Needle in Relapsed/Refractory Myeloma

May 14th 2021

Novel combinations are paramount for patients with relapsed/refractory multiple myeloma who are in second relapse or beyond; some isatuximab-irfc–containing regimens have the potential to move to the frontline setting and combining melphalan flufenamide with proteasome inhibitors and anti-CD38 monoclonal antibodies is an active area of interest.

Universal Genetic Testing Reveals Variants Linked With Increased Cancer Risk in CRC

May 13th 2021

One in 6 patients with colorectal cancer harbor genetic changes that substantially increase their risk for cancer, especially in those who are younger at the time of diagnosis.

3-Month Adjuvant CAPOX Represents Potential Option for Select High-Risk Stage II CRC

May 13th 2021

Three months of adjuvant capecitabine plus oxaliplatin represents a potential option for select patients with high-risk stage II colorectal cancer due to its convenience, reduced toxicity, and cost, although noninferiority to the 6-month standard duration was not demonstrated.

Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer

May 12th 2021

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC

May 8th 2021

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Bachelot Spotlights Impact of Tucatinib for CNS Metastases in HER2+ Breast Cancer

May 8th 2021

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

Building Off the Success Seen With Immunotherapy Strategies in NSCLC

May 7th 2021

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

KATHERINE and FeDeriCa Trials Shift Standards in Early-Stage HER2+ Breast Cancer

May 6th 2021

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

Quadri Calls for Integration of Surgery Into Evolving Locally Advanced Lung Cancer Paradigm

May 6th 2021

Syed M. Quadri, MD, discusses the role of surgery in early-stage and locally advanced lung cancer, as well future directions with robotic and minimally invasive surgery.

Trastuzumab Deruxtecan Under Investigation in HER2+ CRC in DESTINY-CRC02 Trial

May 3rd 2021

The first patient has received treatment with fam-trastuzumab deruxtecan-nxki in the phase 2 DESTINY-CRC02 trial, which is exploring the safety and efficacy of the antibody-drug conjugate in patients with HER2-overexpressing, BRAF wild-type, RAS-mutant or wild-type or mutant locally advanced, unresectable or metastatic colorectal cancer who have progressed following treatment with standard chemotherapy.

DPX-Survivac/Pembrolizumab Plus Cyclophosphamide to Be Examined in DLBCL

May 3rd 2021

Following feedback from the FDA, IMV Inc. and Merck have entered into an agreement to open a phase 2b clinical trial examining the combination of maveropepimut-S and pembrolizumab plus low-dose cyclophosphamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

PARP Inhibitors Pave Way for Personalized Care in CRPC

April 30th 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab Shows Early Promise in DSRCT

April 29th 2021

Intraperitoneal radioimmunotherapy with the anti-B7H3 murine monoclonal antibody 131I-omburtamab was well tolerated with low radiation exposure to normal organs, making it a feasible option to combine with other therapies in patients with desmoplastic small round cell tumor.

Hutson Dives Into Controversial Depths: When Is Nephrectomy Appropriate in RCC?

April 28th 2021

In patients with renal cell carcinoma, factors that determine whether a partial or full nephrectomy should be performed include tumor location and size, but efforts should be made to perform partial nephrectomies whenever possible to preserve kidney function.

Trilaciclib Added to NCCN Guidelines for SCLC and Hematopoietic Growth Factors

April 27th 2021

The National Comprehensive Cancer Network® has added the CDK4/6 inhibitor trilaciclib to its Clinical Practice Guidelines in Oncology for small cell lung cancer as well as for supportive care for hematopoietic growth factors.

PD-1 Regimens Lead Charge Against Gastrointestinal Cancers

April 25th 2021

With immunotherapy options expanding for patients with a range of gastrointestinal cancers to include combination strategies with chemotherapy, their use in the treatment course should come sooner rather than later for those with high PD-L1 expression.

Gradishar Highlights Cetirizine as Management Tool for Hypersensitivity Infusion Reactions in Breast Cancer and Beyond

April 23rd 2021

William Gradishar, MD, discusses the phase 2 data evaluating the activity with IV cetirizine and its potential use in patients with breast cancer.